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Human cytomegalovirus (HCMV), a member of the 
β-herpesvirus family, has been recognised as one of the
most important pathogens in immunocompromised indi-
viduals (Speich & Van der Bij, 2001; Heininger et al.,
2001), particularly when the deficiency affects cell-mediat-
ed immune responses (such as in HIV-infected patients), as
well as immunosupressed individuals (solid organ and allo-
genic bone marrow recipients) (Manfredi & Chiodo,
2001).
This pathogen is the most common congenital viral
infection in humans due to the high prevalence of the virus
in the general population, with up to 90% of the urban
population infected (Trincado et al., 2000). Although it is
well known that highly active antiretroviral therapy has
substantially decreased the incidence of HCMV retinitis in
AIDS patients (Lee et al., 2001), this change does not indi-
cate that it is no longer of concern (Whitley et al., 1998;
Nichols & Boeckh, 2000). On the contrary, HCMV dis-
ease in solid organ recipients, newborns, and even in AIDS
patients still accounts for considerable morbidity, and drug
resistance to the anti-HCMV compounds offers a great
challenge for medicinal chemistry research (Emery, 2001).
In our search for new antiviral agents, we initially dis-
covered the 2,1,3-benzothiadiazine dioxide (BTD) modi-
fied acyclonucleosides with a marked activity against
HCMV and varicella-zoster virus (Martinez et al., 1997;
1999a). In order to obtain further insight into the structur-
al requirements for the biological activity of the BTD fam-
ily we have carried out several modifications based not only
on traditional structure-activity relationship (SAR) studies
(Martinez et al., 1999b; 2000a), but also on three-dimen-
sional quantitative SAR methods (Martinez et al., 2000b).
These results led us to maintain, and in some cases to
improve, the antiviral activity in the second generation of
BTD compounds (Figure 1).
The disubstituted BTD derivatives depicted in Figure 1
are potent non-nucleosidic HCMV-inhibitors with a new
and interesting inhibition profile acting in the initial stages
of the viral replicative cycle (Martinez et al., 2000a,b;
2001).
To assess the therapeutic potential of BTD derivatives
for the treatment of immunosupressed diseases, such as
AIDS, the antiviral screening against HIV has been carried
out. Here we report the results on the antiviral evaluation
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Antiviral assays carried out on the potent 
benzothiadiazine dioxide (BTD) human
cytomegalovirus (HCMV) inhibitors have led us to
find marginal but selective anti-HIV-1 activity.
Specific pharmacological studies, such as time of
addition experiments and assays on specific viral
strains with mutations on its reverse transcriptase,
have indicated that BTD compounds act as non-
nucleoside reverse transcriptase inhibitors.
Theoretical calculations showed a 
butterfly conformation for the active derivatives
that are compatible with their mechanism of
action. Therefore, BTD derivatives can be consid-
ered as potential lead compounds for the treat-
ment of opportunistic HCMV infections in
immunocompromised individuals such as AIDS
patients.
Keywords: HIV-1, human cytomegalovirus, ben-
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Figure 1. Benzothiadiazine dioxides human
cytomegalovirus-inhibitors
R′ and R represent, for example, H, 4NO2 or 4OMe.
against HIV of some of the previously described BTD
compounds (1–19) (Figure 2).
Materials and methods
Cells
MT-4 (Miyoshi et al., 1982) and CEM (Foley et al., 1965)
cells were grown and maintained in RPMI 1640 medium,
supplemented with 10% heat-inactivated fetal calf serum,
2 mM l-glutamine, 0.1% sodium bicarbonate and 20 µg of
gentamicin/ml.
Antiretroviral evaluation
HIV-1 (HTLV-IIIb) was kindly provided by Dr RC Gallo
(when at the National Institutes of Health, Betheseda,
Md., USA). Virus stocks were prepared from the super-
natants of HIV-1-infected MT-4 cells. HIV-2 (strain
ROD) was provided by Dr L Montagnier (Pasteur
Institute, Paris, France) and virus stocks were prepared
from the supernatants of HIV-2-infected MT-4 cells.
CEM cells were obtained from the American Tissue
Culture Collection (Rockville, Md., USA). CEM cells
were infected as follows: 4×105 cells/ml were infected with
HIV-1 or HIV-2 at ~100 CCID50 (50% cell culture infec-
tive dose) per ml of cell suspension. Then 100 µl of the
infected cell suspension were transferred to 96-well
microtitre plate wells and mixed with 100 µl of the
appropiate dilutions of the test compounds. After 4 days
the HIV-infected cell cultures were examined microscopi-
cally for giant cell formation.
Cytotoxicity assays
Cytotoxicity measurements were based on the inhibition of
MT-4 and CEM cell growth. MT-4 or CEM lymphocytes
were seeded at a rate of 5×103 cells/well microtitre plates
and allowed to proliferate for 24 h. Different concentra-
tions of the test compounds were then added (in duplicate),
and after 3 days of incubation at 37°C in 5% CO2 atmos-
phere, the cell number was determined with a coulter
counter. Cytotoxicity is expressed as CC50, which repre-
sents the compound concentration required to reduce cell
growth by 50%.
Results
In vitro anti-HIV activity
The anti-HIV evaluation of BTD 1–19 against HIV-1
(strain IIIB) and HIV-2 (strain ROD) in two different cell
lines of human T-lymphocytes (CEM and MT-4 cells
respectively) were performed following standard proce-
dures (De Clercq, 1994; Pauwels et al., 1988). Their antivi-
ral activity values expressed as the 50% of effective concen-
tration (EC50) are collected in Table 1.
Several compounds were found to inhibit the replication
of HIV-1 and HIV-2 at a concentration that was only two-
to fivefold below the cytotoxic concentration for the host
cells. However, some other derivatives, such as 3, 6, 17 and
19, showed selectivity indices with values up to 10 against
HIV-1 and were completely inactive against HIV-2 which
point to a virus specific action.
Time of addition experiments
This experiment investigates which step of the replication
cycle of HIV is inhibited by an anti-HIV compound. It
determines how long after infection the addition of the
compound can be postponed before losing its antiviral
activity in one replication cycle. Reference compounds with
a known mode of action were included. In this case we used
dextran sulfate, a polyanion which is known to interfere
with binding of the virus to the cell; the nucleoside ana-
logue zidovudine (AZT), which inhibits the reverse tran-
scription process; and ritonavir, which is an inhibitor of the
proteolytic cleavage. Inhibition of viral replication was
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Figure 2. BTD derivatives evaluated against HIV-1
and HIV-2
Anti-HIV-1 activity of BTD HCMV-inhibitors
measured as the logarithm of viral antigen production p24
(log p24), in function of time post infection at which the
compound was added to a culture of infected HIV-1 MT-4
cells. The results are shown in (Figure 3). Addition of BTD 3
can be postponed for 3 h after infection, showing the same
graphical profile in this experiment of the reverse transcrip-
tase (RT) inhibitor AZT. These data suggest a viral interac-
tion of BTD 3 proximately at the moment of reverse tran-
scription of HIV.
Inhibitory activity of BTD against NNRTI-resistant
mutant HIV-1 strain
To determine the BTD binding site to RT, BTD 3, as well as
AZT (nucleoside reverse transcriptase inhibitor [NRTI]),
nevirapine (non-nucleoside reverse transcriptase inhibitor
[NNRTI]) and indinavir (protease inhibitor), were evaluated
against an HIV-1 strain with specific mutations in its RT
(K103N and Y181C) that make it resistant to NNRTIs.
AZT and indinavir retain their antiviral activity (EC50 values
of 0.004 and 0.018 µM, respectively), whereas BTD 3 and
nevirapine markedly lost their capacity to inhibit HIV-1
replication (EC50 values >50 and >15 µM, respectively). This
fact points out that BTD derivatives exert their anti-HIV
action by interaction with the HIV RT in the same allosteric
pocket as the known NNRTIs.
Molecular modeling of BTD 3
A preliminary conformational study of BTD 3 was carried
out using ab initio Hartree–Fock methods. The molecular
geometry was fully optimized with HF/3-21G* and HF/6-
21G*, using Gaussian 94 program (Frisch et al., 1995), to
determine the optimum position of the two aromatic systems.
The optimized geometry shows a disposition of the aromatic
system in agreement with a butterfly-like configuration with
a valence angle α between the two rings of 111° (Figure 4).
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Table 1. Anti-HIV activity (HIV-1, strain IIIB and HIV-2 strain ROD) of BTD derivatives 1–19 in CEM and MT-4 cells
CEM MT-4
EC50 (µM)* CC50 (µM)† EC50 (µM)* CC50 (µM)†
No. HIV-1 (IIIB) HIV-2 (ROD) HIV-1(IIIB) HIV-2 (ROD)
1 25.0 ±7.1 25.0 ±7.1 27.7 ±4.3 >44 >44 44.2 ±9.4
2 25.0 ±2.8 >50 108 ±51.5 20.3 ±0.9 >125 >125
3 5.0 ±2.6 >10 27.8 ±0.1 18.4 ±10.5 >38 37.6 ±8.6
4 >10 7.5 ±3.5 35.8 ±3.3 >125 >125 >125
5 >2 >2 16.4 ±3.4 >125 >125 >125
6 2.0 ±0.9 18.0 ±17.0 82.0 ±11.7 12.0 ±4.0 >125 >125
7 6.5 ±0.7 >10 14.7 ±0.3 >125 >125 >125
8 >10 >10 21.9 ±2.1 >125 >125 >125
9 8.0 ±2.8 >10 19.4 ±0.1 241.9 ±2.1 >125 >125
10 5.0 ±1.4 >10 22.4 ±0.1 >104 >104 >104
11 >10 >10 30.5 ±0.3 >125 >125 >125
12 >50 >50 >250 >68 >68 67.5 ±48.2
13 >10 >10 23.2 ±0.2 66.2 ±6.5 >60 66.2 ±6.5
14 >10 >10 22.8 ±3.3 >125 >125 >125
15 >10 >10 24.7 ±4.7 >125 >125 >125
16 >10 >10 28.7 ±5.9 60.1 ±5.2 >68 60.1 ±5.2
17 3.0 ±1.4 >10 21.3 ±5.3 8.5 ±0.3 >125 >125
18 >10 >10 >10 >125 >125 >125
19 4.5 ±2.1 >10 21.6 ±1.4 8.1 ±1.0 >68 71.0 ±8.5
*EC50, 50% effective concentration.
†CC50, 50% cytotoxic concentration.
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Figure 3. Effect of the time addition of BTD 3 and
control drugs on MT-4 cells infected by HIV-1
AZT, zidovudine; BTD, benzothiadiazine dioxide
Discussion
BTDs are a promising new class of anti-HCMV inhibitors
that have shown a marginal but selective anti-HIV-1 activ-
ity, representing an important hit among the antiviral
drugs. Combination of anti-HCMV and anti-HIV activi-
ties in a single compound could prove an efficient strategy
for the treatment of acute HCMV infection in AIDS
patients, while simultaneously combating the primary HIV
infection.
The anti-HIV-1 data shown in Table 1 led us to estab-
lish preliminary SARs. The length of the linker between
the aromatic ring attached to the N1 of the thiadiazine
framework is crucial for activity (see the lack of activity of
compounds 1 and 13–15 versus 2–10), pointing to addi-
tional interactions with the viral enzyme. The activity
found in BTDs 17 and 19 opens the possibility of chang-
ing the electronic nature of substituents attached to N1 for
increased anti-HIV-1 activity. However, for the develop-
ment of single compounds that retain both antiviral activi-
ties (anti-HCMV and anti-HIV-1), the structure-activity
relationships derived for the first antiviral activity found in
these compounds should also be considered (Martinez et
al., 2000a).
Regarding the anti-HIV-1 activity described here, the
time of addition experiments allowed us to establish the
point in the HIV-1 replicative cycle at which BTD deriva-
tives could act. The behaviour found for BTD 3 is the same
as that shown for the known RT inhibitor AZT (Figure 3),
suggesting a viral interaction approximately at the moment
of reverse transcription of HIV. Furthermore, the lack of
anti-HIV-1 activity of BTD 3 on viral strains with specific
mutations on its RT that make it resistant to NNRTIs,
points to a mechanism of action similar to those of the
NNRTIs.
NNRTIs bind to RT in a largely hydrophobic pocket
whose shape varies only slightly for different NNRTIs.
Thus, complementarity with the pocket shape, rather than
with the pocket charge, is the crucial factor in determining
the binding mode of many NNRTIs. In this context, it is
well known that NNRTIs comprise a structurally diverse
family sharing some common three-dimensional feature.
Their shape is a butterfly-like conformation that fits well
into a complementary cavity in the enzyme. In general,
NNRTIs can adopt this shape with two hydrophobic moi-
eties connected by a linker group that allows the two wings
to bend with an angle of 110–115° (Mager, 1996). The
molecular modelling performed on BTD 3 showed a con-
formation compatible with this bioactive configuration.
In summary, we have shown an anti-HIV-1 NNRTI
profile of BTD HCMV inhibitors. These compounds can
be considered as potential leads in the treatment of oppor-
tunistic infections in immunocompromised individuals,
such as AIDS patients. Further studies are in progress to
optimize this new therapeutic action found on BTD deriv-
atives.
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